Clinical Trials

Date: 2012-02-08

Type of information: Completion of the trial

phase: 1

Announcement: completion of the trial

Company: GeNeuro (Switzerland)

Product: GNbAC1

Action mechanism: monoclonal antibody. The  monoclonal antibody GNbAC1 targets the envelope protein of an endogenous retrovirus which could play a critical role in the pathogenesis of Multiple Sclerosis. Discovered in the early 90’s, the Human endogenous retrovirus of type W is closely associated with MS and, due to its neurotoxic properties, could be a causal factor of the disease.

Disease: multiple sclerosis

Therapeutic area: Autoimmune diseases - Neurodegenerative diseases

Country:

Trial details:

• This Phase I study is a single ascending dose study focusing on the safety and pharmacokinetics of the monoclonal antibody. During the study, 33 subjects have received the monoclonal antibody up to the maximal dose which was very well tolerated.

Latest news:

• GeNeuro has announced the successful completion of its phase I clinical study with GNbAC1, a humanized monoclonal antibody targeting a human endogenous retrovirus, to treat multiple sclerosis. The randomized, double-blind, placebo-controlled, phase I study of single ascending intravenous doses of GNbAC1 in healthy volunteers demonstrated that GNbAC1 is very well tolerated.
• GeNeuro’s next step is to administer the monoclonal antibody to MS patients in clinical studies which will start within the next months.

Is general: Yes